Noticias de DNLI_US

Noticias del mercado

Últimas noticias sobre DNLI_US — 142 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: DNLI_US ✕ 142 resultados
26/03/2026 DNLI_US — Yahoo Finance
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
26/03/2026 DNLI_US — Stock Titan
Vanguard disaggregation: no beneficial DNLI shares reported (DNLI)
26/03/2026 DNLI_US — Benzinga
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease
26/03/2026 DNLI_US — GuruFocus ES ← EN
Denali Therapeutics (DNLI): Goldman Sachs eleva el precio objetivo a 40 dólares | Noticias de acciones de DNLI
26/03/2026 DNLI_US — MarketScreener
Deutsche Bank Raises Price Target on Denali Therapeutics to $35 From $26, Keeps Buy Rating
26/03/2026 DNLI_US — BioSpace
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA's Hunter Syndrome Nod
26/03/2026 DNLI_US — GuruFocus
Denali Therapeutics (DNLI) Receives Analyst Rating Update from B
26/03/2026 DNLI_US — GuruFocus
Denali Therapeutics (DNLI): Goldman Sachs Raises Price Target to $40 | DNLI Stock News
25/03/2026 DNLI_US — Stock Titan
First new Hunter syndrome treatment in 20 years wins FDA approval
25/03/2026 DNLI_US — Yahoo Finance
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
25/03/2026 DNLI_US — Reuters
US FDA approves Denali's genetic disorder therapy for children
25/03/2026 DNLI_US — BioCentury
Denali approval revives surrogate-endpoint path in neuronal MPS
25/03/2026 DNLI_US — Investing.com
Stifel raises Denali Therapeutics price target on drug approval
25/03/2026 DNLI_US — Investing.com
Goldman Sachs raises Denali Therapeutics stock price target on FDA approval
25/03/2026 DNLI_US — Investing.com
Oppenheimer raises Denali Therapeutics price target on FDA approval
25/03/2026 DNLI_US — Seeking Alpha
Denali stock gains on FDA nod for lead asset (DNLI:NASDAQ)
25/03/2026 DNLI_US — Investing.com
BTIG raises Denali Therapeutics price target to $38 on drug approval
25/03/2026 DNLI_US — Stock Titan
FDA clears Denali (NASDAQ: DNLI) AVLAYAH therapy for Hunter syndrome
25/03/2026 DNLI_US — TipRanks
Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy
25/03/2026 DNLI_US — Bitget
Denali Therapeutics Inc. announced that its new drug Avlayah will soon be available on the US market after receiving regulatory approval.

Página 6 de 8

keyboard_arrow_up